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Abstract
Introduction In acute lung injury, repair of the damaged alveolar-
capillary barrier is an essential part of recovery. Endostatin is a
20 to 28 kDa proteolytic fragment of the basement membrane
collagen XVIII, which has been shown to inhibit angiogenesis via
action on endothelial cells. We hypothesised that endostatin
may have a role in inhibiting lung repair in patients with lung
injury. The aims of the study were to determine if endostatin is
elevated in the plasma/bronchoalveolar lavage fluid of patients
with acute lung injury and ascertain whether the levels reflect the
severity of injury and alveolar inflammation, and to assess if
endostatin changes occur early after the injurious lung stimuli of
one lung ventilation and lipopolysaccharide (LPS) challenge.
Methods Endostatin was measured by ELISA and western
blotting.
Results Endostatin is elevated within the plasma and
bronchoalveolar lavage fluid of patients with acute lung injury.
Lavage endostatin reflected the degree of alveolar neutrophilia
and the extent of the loss of protein selectivity of the alveolar-
capillary barrier. Plasma levels of endostatin correlated with the
severity of physiological derangement. Western blotting
confirmed elevated type XVIII collagen precursor levels in the
plasma and lavage and multiple endostatin-like fragments in the
lavage of patients. One lung ventilation and LPS challenge
rapidly induce increases in lung endostatin levels.
Conclusions Endostatin may adversely affect both alveolar
barrier endothelial and epithelial cells, so its presence within
both the circulation and the lung may have a pathophysiological
role in acute lung injury that warrants further evaluation.
Introduction
Acute lung injury (ALI) is characterised by neutrophilic inflam-
mation of the alveolar-capillary barrier. ALI has multiple aetiol-
ogies, but appears to follow a uniform pattern of injury at a
cellular level. Extensive damage to the alveolar-capillary barrier
leads to the influx of a protein-rich oedema fluid and accompa-
nying inflammatory cells into the alveoli. A complex cascade of
both inflammatory and anti-inflammatory cytokines is triggered
and inflammatory cells, including neutrophils and monocytes,
are recruited to the alveoli. Studying these processes early in
the course of the disease can be challenging because most
insults causing lung injury are not predictably timed.
ANOVA: analysis of variance; ALI: acute lung injury; APACHE II: acute physiology and chronic health evaluation II; BAL: bronchoalveolar lavage; 
BALF: bronchoalveolar lavage fluid; ELF: epithelial lining fluid; ELISA: enzyme-linked immunosorbent assay; FEV: forced expiratory volume; FiO2: frac-
tion of inspired oxygen; ICU: intensive care unit; Ig: immunoglobulin; IL: interleukin; IQR: interquartile range; LPS: lipopolysaccharide; MAPK: mitogen 
activated protein kinase; MMP: matrix metalloproteinases; OD: optical density; OLV: one lung ventilation; PaO2: partial pressureof arterial oxygen; 
PBS: phosphate-buffered saline; SAPS II: simplified acute physiology score II; SD: standard deviation; SEM: standard error of the mean; TNF: tumour 
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Two human models of lung injury allow assessment of the early
phases of ALI. One lung ventilation (OLV) during oesophagec-
tomy is associated with a significant post-operative risk of ALI
with proposed causative mechanisms including the ischae-
mic/reperfusion insult experienced by the collapsed lung, oxi-
dative stress injury and barotrauma to the ventilated lung [1].
Systemic levels of inflammatory cytokines have been shown to
relate to the duration of OLV and to be reduced by temporary
ventilation of the collapsed lung [2]. In addition, recently there
have been several studies looking at lipopolysaccharide (LPS)
challenge in human volunteers. This model induces a signifi-
cant neutrophilia in the bronchoalveolar lavage (BAL) with dis-
ruption of the alveolar-capillary barrier and allows early
pathophysiological changes within defined time limits to be
assessed.
The neutrophilic inflammation of the alveolar capillary barrier in
ALI and the models of OLV or LPS challenge result in the
release of proteases including collagenases [3]. The balance
between collagen formation and degradation is a complex and
dynamic process within the lung of patients with ALI [4]. BAL
studies suggest changes in collagen production and degrada-
tion may promote collagen deposition within the lung, even at
the onset of lung injury [4,5].
There are at least 27 different species of collagen. Types I and
III predominate within both healthy and fibrotic lung [6].
Perivascular tissue contains type XVIII collagen which is
expressed as three variable polypeptide forms (SHORT, MID-
DLE and LONG/frizzled) [7] (Figure 1). Endostatin is a 20 kDa
proteolytic fragment of collagen XVIII. Recombinant endosta-
tin has been shown to inhibit tumour growth and metastasis in
animal models [8]. On the cellular level, endostatin specifically
blocks growth factor-induced proliferation and migration of
endothelial cells. The latter is proposed to involve integrin
binding and subsequent disruption of the cell-matrix interac-
tion either via Src tyrosine kinase/Rho pathway or mitogen
activated protein kinase (MAPK)/p38 pathway [9-11].
Endostatin induces endothelial cell apoptosis in microgram
doses [12], inhibits vascular endothelial growth factor (VEGF)-
mediated signalling due to a direct interaction with VEGF
receptor-2 [13], and inhibits cyclin D1 [14] and Wnt signalling
[15]. The main focus of research into endostatin has been its
anti-tumour effects. Recently, however, elevated levels have
been found in the plasma of patients with preeclampsia, a con-
dition also associated with pan-endothelial damage [16].
There is little information about the effects of endostatin on
epithelial cells; however, it was shown to inhibit squamous cell
carcinoma migration and invasion in vitro [17,18].
Resolution of ALI is dependent on the successful repair of a
confluent barrier of alveolar epithelial and endothelial cells
[19]. This process requires cell division and migration. Mole-
cules that effect cell proliferation, migration and repair are
therefore potential therapeutic agents in ALI [20]. As collagen
degradation products are elevated in the lungs of patients with
ALI [4], we hypothesised that endostatin may have a role in
inhibiting lung repair in patients with ALI. The aim of this study,
therefore, was to test the hypothesis that endostatin is ele-
vated in the plasma and BAL of patients with ALI and to deter-
mine whether endostatin levels reflect the severity of injury and
alveolar inflammation. In addition, we assessed changes in
endostatin in OLV and LPS challenge models of early lung
injury.
Materials and methods
Subjects
All patients enrolled in the study gave written informed con-
sent themselves at the time of enrollment, or it was given by
the consultant in charge of the intensive care unit (ICU) (not
Figure 1
Schematic representation of the human collagen XVIII variants, termed as SHORT, MIDDLE and LONG/FZ Schematic representation of the human collagen XVIII variants, termed as SHORT, MIDDLE and LONG/FZ. Collagenous sequences are shown in 
white. Non-collagenous (NC) amino terminal sequences common to all variants are shown in black. Non-collagenous amino terminal sequences 
common to the two long variants are shown in grey. A non-collagenous amino terminal sequence specific to the LONG/FZ variant is marked with 
waves. The amino acid lengths (aa) and the predicted molecular masses (kDa) of these sequences are given, as are those of the full length type XVIII 
collagen molecules. Signal sequences are indicated by vertical and horizontal hatching. The epitopes of the antibodies used in this work are shown 
by black horizontal lines. The molecular masses of some endostatin-containing carboxy-terminal fragments are also indicated.Available online http://ccforum.com/content/13/2/R52
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part of the research team) as their legal guardian if they were
unable to give consent because of sedation and ventilation. In
addition, in all cases, patients' next of kin gave informed signed
assent to inclusion. In the UK. patients' relatives cannot con-
sent for incapacitated relatives. In addition, those patients who
recovered mental competency during their inpatient stay retro-
spectively provided signed consent for their inclusion in the
study. This study was fully approved by the local National
Health Service trusts and ethical review committee.
Patients were studied within 48 hours of admission to the ICU
of Birmingham Heartlands and University Hospital, Birming-
ham, UK, between 2006 and 2008. 38 patients (22 male,
mean age 62 years, standard deviation (SD) 16 years, 12 with
direct and 21 with remote lung injury) were identified as having
ALI according to the American-European consensus state-
ment [21]. Patients were ventilated using pressure-controlled
ventilation. Bronchoscopy and BAL was performed in all
patients immediately following inclusion and, when possible,
four days later (n = 22). The median time between patients sat-
isfying the criteria for ALI and initial bronchoscopy was about
six hours (range = 3 to 36) Of the patients who did not
undergo repeat bronchoscopy, six had died, five had been
extubated and five had contraindications. Ten ventilated
patients with identifiable risk factors for ALI but who did not
satisfy the consensus criteria for ALI were recruited as con-
trols (6 male, mean age 59 years, SD 15 years). Ten non-
smokers underwent bronchoscopy as normal controls.
Patient demographic characteristics were recorded at base-
line. The acute physiology and chronic health evaluation II
(APACHE II) and simplified acute physiology score II (SAPS II)
were recorded as global markers of disease severity. The Mur-
ray lung injury score, partial pressure of arterial oxgen (PaO2):
fraction of inspired oxygen (FiO2) ratio was recorded on the
day of bronchoscopy. A summary of patient physiological
severity is shown in Table 1.
Post-one lung ventilation patients
Ten patients (9 males, 1 female, age 63 years, mean forced
expiratory volume (FEV) 1 94% predicted, mean 25 pack-year
smoking history) undergoing elective oesophagectomy for
oesophageal carcinoma underwent BAL of the collapsed lung
at the end of the operation, which as such potentially suffers
from ischaemia-reperfusion injury. Ventilation was performed
with pressure control for eight patients and two patients with
volume control. Mean peak airway pressures were 25.8 cm,
standard error of the mean (SEM) 0.88 cm, and a mean tidal
volume of 430 ml was achieved. Mean duration of OLV was
189 minutes, SEM 22.29 minutes. The preoperative
PaO2:FiO2 ratio was a mean of 50.210, SEM 3.45, and imme-
diate post-operative PaO2:FiO2 ratio was a mean of 40.2, SD
14.46, SEM 4.57, and average intraoperative FiO2 during OLV
was 67%. None of these patients went on to develop early
lung injury.
Inhaled lipopolysaccharide-induced model of lung injury
We include data from a human LPS challenge study assessing
the anti-inflammatory effects of simvastatin versus placebo in
healthy volunteers. Data are presented from 10 patients
treated with placebo (five males, mean age 26 years) who
underwent bronchoscopy six hours post-inhalation of LPS. Full
details of the patient characteristics and lavage fluid abnormal-
ities are available in another paper [22].
Bronchoscopy and bronchoalveolar lavage
Bronchoscopy was performed by instilling three 50 ml aliquots
into the right middle lobe (median yield in ALI patients = 65 ml,
IQR = 35 to 80 ml). Bronchoalveolar lavage fluid (BALF) was
processed as described previously [23]. Into lithium heparin
tubes (Becton Dickinson, London, UK), 15 ml of blood was
collected simultaneously and stored on ice until processing.
Lipopolysaccharide challenge
LPS (Escherichia coli serotype O26:B6; Sigma Chemicals,
Poole, Dorset, UK) was dissolved in endotoxin-free sterile
0.9% saline and inhaled via an automatic inhalation–synchro-
nised dosimeter nebuliser (Spira Electra 2, Hameenlinna, Fin-
Table 1
Characteristics of acute lung injury and septic at-risk patients
Characteristic ALI At risk for ALI P value 95% confidence interval
PaO2:FiO2 ratio 130 (40) 255 (92) 0.001 75 to 167
Lung injury score 2.6 (0.4) 1.2 (0.3) 0.001 1.0 to 1.5
APACHE II 24.5 (8.2) 21.7 (8.9) 0.294 2.5 to 8.2
SAPS II 57.4 (17.5) 54.8 (12.8) 0.631 -8.3 to 13.5
SOFA score 8.9 (2.8) 6.6 (4.3) 0.116 -0.8 to 5.5
ALI = acute lung injury; APACHE = acute physiology and chronic health evaluation; FiO2 = fraction of inspired oxygen; PaO2 = partial pressure of 
arterial oxygen; SAPS = simplified acute physiology score; SOFA = sequential organ failure assessment. Data are expressed as mean (standard 
deviation).Critical Care    Vol 13 No 2    Perkins et al.
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land), which delivers particles of a mass median aerodynamic
diameter of 10 mm, as described previously. The dosimeter
produces a calibrated aerosol of 8 μl at each slow inhalation
starting from functional residual capacity to total lung capacity.
Each subject performed five successive inhalations of the LPS
solution (1.25 mg/ml) through the mouthpiece with a nose clip
in place. The total dose of inhaled LPS was 50 μg. BAL was
performed six hours after LPS inhalation according to stand-
ard guidelines by a single researcher (DM).
Urea and protein determination
Urea concentration was determined using a commercially
available urea kit (Sigma diagnostics, Poole, UK). The epithe-
lial lining fluid (ELF) levels of endostatin were estimated using
the following formula: ELF endostatin = BAL urea (mmol/L) ×
BAL endostatin/plasma urea concentration (mmol/L), as
described previously [24]. BALF protein was measured using
the Lowry method [25]. The protein permeability index was
calculated as plasma protein/BAL protein [26].
ELISA
Endostatin and IL-8 were measured by using an ELISA kit
(R&D systems, Abingdon, UK) according to manufacturer's
instructions. CV for intra-assay variability in BALF of endostatin
is 3.6% and inter-assay variability was 8%. Spiking ALI BALF
with recombinant endostatin standard (2.5 ng/ml) has a 96%
recovery rate.
Western blotting of BALF and plasma samples
Immunoprecipitation and western blotting of plasma and BALF
was performed using methods described previously [27,28].
The specificities of the two polyclonal human collagen XVIII
antibodies, anti-ALL huXVIII (QH48.18) and anti-LONG huX-
VIII (QH1415.7), have been verified earlier using competitive
blot with the peptides that were used to generate these anti-
bodies [7,27,29]. The following in house-developed antibod-
ies were used in these studies in order to detect the precursor
forms of type XVIII collagen and any degradation products:
Anti-LONG huXVIII is a polyclonal anti-LONG human type
XVIII collagen antibody which targets the N-terminal end of the
two longer isoforms of XVIII collagen [30]. Anti-ALL huXVIII is
a polyclonal human type XVIII antibody which targets the N-ter-
minal end common to all three collagen XVIII isoforms [7]. A
polyclonal anti-endostatin antibody known to detect proteolyt-
ically cleaved endostatin fragments [30].
Western blotting of BALF samples
A 25 μl sample of BALF was loaded onto polyacrylamide gel
and the proteins were separated on a 7 to 12% SDS-PAGE
under reducing conditions, electrotransferred to a nitrocellu-
lose membrane (Protran; Schleicher & Schuell, Dassel, Ger-
many) and probed with rabbit polyclonal antibodies against
endostatin (HES.6) [28] and human collagen XVIII (anti-all
huXVIII QH4818 and anti-long huXVIII, QH1415.7) [7], all
used at a concentration 1 μg/ml in 5% fat-free milk powder in
1 × PBS, followed by a horseradish peroxidase-conjugated
goat anti-rabbit antibody (Bio-Rad, Abingdon, UK). After wash-
ing the membrane extensively with 1 × PBS/0.1% Tween, the
proteins that were reactive to collagen XVIII and endostatin
antibodies were visualised with ECL western blotting detec-
tion reagents (Amersham Pharmacia Biotech, Amersham, UK).
For binding sites of antibodies to type XVIII collagen see Fig-
ure 1.
Immunoprecipitation and western blotting of plasma 
samples
Collagen XVIII was immunoprecipitated from human plasma
using a monoclonal anti-ALL type XVIII antibody, DB144-N2
bound to anti-mouse IgG-coated magnetic beads (Dynabeads
M-280; Dynal, Malmo, Sweden), as described elsewhere [31].
The bound polypeptides were separated on a 7% SDS-PAGE
under reducing conditions, electrotransferred to a nitrocellu-
lose membrane and probed with rabbit polyclonal antibodies
anti-all huXVIII (QH48.18) or anti-long huXVIII (QH1415.7)
[7], both at a concentration of 1 μg/ml in 5% fat-free milk pow-
der in 1 × PBS, followed by a horseradish peroxidase-conju-
gated goat anti-rabbit antibody. After washing the membrane
extensively, the proteins reactive to collagen XVIII antibodies
were visualised with ECL western blotting detection reagents.
For binding sites of antibodies to type XVIII collagen see Fig-
ure 1.
Statistical methods
The Ryan-Joiner normality test was used to test the distribution
of the data. Non-parametric Mann-Whitney U tests were used
for data that was not normally distributed (ELISA endostatin
ALI plasma data and BALF data) and are quoted as medians
(interquartile ranges (IQR)). Normally distributed data (optical
density data for blots) are quoted as mean (SEM) and com-
pared using analysis of variance (ANOVA). Statistical signifi-
cance assumed at P < 0.05.
Results
Plasma levels of endostatin are elevated in patients with 
acute lung injury
Median plasma levels of endostatin were elevated in patients
at the onset of ALI (182 ng/ml, IQR = 111 to 244) compared
with normal controls (median 96.3 ng/ml, P = 0.008) and
patients at risk from ALI (102 ng/ml, P = 0.0094). On day four,
plasma levels in ALI patients remained elevated (182.8 ng/ml,
IQR = 97.8 to 284.6; Figure 2).
There were significant linear associations between plasma
endostatin at the onset of ALI and the global severity of illness
markers APACHE II (r = 0.37, P = 0.038) and SAPS II (r =
0.44, P = 0.007) but not with lung injury score (r = -0.3, P =
0.9) (data not shown). Plasma endostatin levels at the onset of
ALI or at day four did not predict whether patients subse-
quently survived or died.Available online http://ccforum.com/content/13/2/R52
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BALF endostatin is significantly elevated compared with 
normal and at-risk patients
ALI patients had greater endostatin levels in BALF on both day
0 (median ALI 2.6 ng/ml, IQR = 0.24 to 0.64, P = 0.001) and
day 4 (median ALI 1.36 ng/ml, IQR = 0.72 to 2.63, P = 0.01)
than healthy individuals (0.08 ng/ml). ALI day 0 endostatin lev-
els (2.6 ng/ml) were higher than those at risk of ALI (0.6 ng/ml,
IQR = 0.3 to 1.4, P = 0.0017; Figure 3).
Endostatin levels in ALI BALF fell from day 0 to day 4 (day 0
median 2.6 ng/ml, IQR = 1.4 to 5.1; vs day 4 median 1.36 ng/
ml, IQR = 0.76 to 2.9; P = 0.02). There was no difference
between BALF levels at day 0 or day 4 between patients who
died or survived, or those with direct or remote lung injury.
BALF endostatin did not correlate with APACHE II, SAPS II or
lung injury score at day 0 or day 4.
ALI BALF endostatin correlates with BAL neutrophilia 
and protein permeability index
There was also a significant relationship between day 0 BALF
endostatin levels and protein permeability index (r = 0.441, P
= 0.013). In addition, day 0 BALF endostatin levels correlated
with the degree of BAL neutrophilia (r = 0.417, P = 0.034) but
not with total cell count or BALF IL-8. At day 4 endostatin also
correlated strongly with protein permeability index (r = 0.723,
P = 0.002) and total neutrophil counts (r = 0.76, P = 0.007)
(data not shown).
Plasma endostatin is higher than ELF endostatin
Plasma levels of endostatin were significantly higher than cal-
culated ELF levels in the lung (median 182 ng/ml vs ELF 119
ng/ml, 95% confidence interval (CI) diff = 18 to 169; P =
0.016). When ELF levels were lower than plasma levels there
was a significant correlation (r = 0.47, P = 0.001) between
plasma and ELF endostatin at the onset of ALI (data not
shown). However, in some patients, calculated ELF levels
were actually higher than plasma suggesting intra-alveolar
generation of endostatin. Interestingly, at day 4 ELF endostatin
correlated with lung injury score (r = 0.499, P = 0.049) but not
in ALI patients at day 0.
OLV and LPS challenge induce a BAL neutrophilia and 
increase PPI
OLV and LPS challenge induced a BAL neutrophilia and an
increase in protein permeability index (PPI) compared with
normal controls (PPI in OLV: median = 0.00636, IQR =
0.00389 to 0.01188; P  = 0.013 vs normal; PPI in LPS:
median = 0.0025, IQR = 0.0013 to 0.003, P = 0.011 versus
normal; normal PPI = 0.0014, IQR = 0.0008 to 0.0024). Per-
centage of neutrophils in BAL rose from 1.1% (IQR = 0.0 to
2.65) in normal BALF to median 11% (IQR = 2 to 60.5) in OLV
(P = 0.011), and 41% (IQR = 24 to 57) in LPS challenge as
described previously [22].
OLV and LPS challenge increases BALF endostatin
Inhalation challenge with LPS increased BALF endostatin from
a median of 0.08 ng/ml in normal individuals to 0.385 ng/ml
(IQR = 0.285 to 0.448, P  = 0.001) in LPS-challenged
patients. OLV increased BAL endostatin (median compared
with normal and LPs challenge; Figure 4). BALF endostatin
correlated with PPI in the LPS challenge (r = 0.63, P = 0.006)
but not in OLV patients. In contrast, plasma levels of endosta-
tin were not altered by LPS challenge or OLV (data not
shown).
Figure 2
Plasma endostatin levels in patients groups Plasma endostatin levels in patients groups. Endostatin was measured 
by ELISA. Endostatin is significantly elevated in patients with acute lung 
injury compared with normal and at-risk controls. ALI = acute lung 
injury.
Figure 3
BALF endostatin in different patient groups BALF endostatin in different patient groups. Bronchoalveolar lavage 
fluid (BALF) endostatin is significantly elevated in the BALF of patients 
with acute lung injury compared with normal and at-risk controls. Lav-
age was repeated where possible again at day 4 in 23 patients. Levels 
fell significantly from day 0 to day 4 but remained elevated compared 
with normal and at-risk controls. ALI = acute lung injury.Critical Care    Vol 13 No 2    Perkins et al.
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Type XVIII collagen precursors are elevated in both the 
plasma and BALF of patients with ALI compared with 
normal controls
In exploratory experiments performed in five consecutive non-
selected patients, plasma and BALF from patients with ALI
demonstrated increased density and number of fragments of
the circulating precursor forms of type XVIII collagen com-
pared with normal controls. Whole lane densitometric analysis
of the western blot by anti-LONG antibody confirmed
increased plasma precursors in ALI (mean optical density
(OD) = 198, SE 38) compared with normal plasma (mean OD
79.8, SE 7.9, 95% CI = 11.6 to 226, P = 0.037) (representa-
tive gels are shown in Figure 5). Western blotting of the pre-
cipitated proteins with three different antibodies to human
collagen XVIII (anti-ALL, anti-LONG and anti-endostatin)
revealed a main 120 kDa band, which is presumably derived
from the middle variant of collagen, containing the N-terminus
and the collagenous central part of the molecule but lacking
the endostatin domain (Figure 5 and data not shown). Based
on the current knowledge of the structure and properties of
collagen XVIII, the diffuse bands over 170 kDa in the plasma
from some ALI patients are interpreted to represent the long,
potentially glycosylated, forms of collagen XVIII.
There was also a clear increase in collagen XVIII fragments in
BALF detected by the anti-ALL antibody revealing a mean
adjusted whole lane OD of 94.9 (SE 9.3) in ALI compared with
41.21 (SE 4.8) (95% CI = 26.6 to 80.6; P = 0.004) in normal
controls (Figure 6). The anti-ALL antibody does not bind the
carboxy end of type XVIII collagen, so this suggests that type
XVIII collagen precursors are present within the BALF of
patients with ALI. Similarly, using the anti-LONG antibody,
there was evidence of increased BALF levels of the long forms
of collagen XVIII (ALI OD = 54.74 (SE 2.1), normal OD =
40.39, 95% CI = 6.8 to 21.7, P = 0.004) (data not shown).
The main bands of 55 kDa, also detectable with anti-LONG
antibody, and 72 kDa were interpreted to represent proteolytic
N-terminal fragments from the middle form and the short form
of collagen XVIII, respectively (Figure 5 and data not shown).
BALF from ALI patients contain multiple endostatin-like 
fragments
Western blotting of BALF with the HES.6 antibody that recog-
nises the carboxyl (endostatin) e n d  o f  t y p e  X V I I I  c o l l a g e n
revealed increased levels of C-terminal endostatin-containing
fragments of collagen XVIII are present within the BALF of ALI
patients with a fragmentation pattern that was different to nor-
mal controls.
Figure 4
BALF endostatin in the different at-risk groups compared with normal  individuals BALF endostatin in the different at-risk groups compared with normal 
individuals. BALF = bronchoalveolar lavage fluid; LPS = lipopolysac-
charide; OLV = one lung ventilation.
Figure 5
Immunoprecipitation with anti-ALL antibody and detection with anti- LONG huXVIII antibody Immunoprecipitation with anti-ALL antibody and detection with anti-
LONG huXVIII antibody. Elevated type XVIII collagen precursors in the 
plasma of ALI patients compared with normal controls is shown. ALI = 
acute lung injury.
Figure 6
Western blot by anti-ALL huXVIII antibody Western blot by anti-ALL huXVIII antibody. It shows elevated type XVIII 
collagen precursors in the bronchoalveolar lavage fluid (BALF) of 
patients with acute lung injury compared with normal controls. ALI = 
acute lung injury.Available online http://ccforum.com/content/13/2/R52
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Control samples contained a strong 55 kDa band extending to
the central collagenous domain, full-length collagen XVIII pre-
cursors between 130 and 170 kDa, and some samples also
showed a clear 20 kDa endostatin band. In addition to these
bands, ALI samples showed a pattern of endostatin-containing
fragments varying in size from 22 to 50 kDa. Histidine-labelled
recombinant endostatin was used as a positive control (Mw
22 kDa). Whole lane densitometric analysis showed that sig-
nificantly elevated amounts of type XVII carboxy terminal
endostatin-like fragments were present in ALI samples (mean
OD = 54, SE 3) compared with normal BALF (mean OD =
43.9, SE 3.87, 95% CI = 2 to 19, P = 0.02) (representative
gel shown in Figure 7).
Discussion
This study has demonstrated that endostatin is elevated within
the plasma and BALF of patients with ALI. Endostatin levels in
ALI BALF reflected the degree of neutrophilia and the extent
of the loss of protein selectivity of the alveolar-capillary barrier.
Plasma levels of endostatin at the onset of ALI were associ-
ated with the severity of physiological derangement. Western
blotting confirmed elevated type XVIII collagen precursor lev-
els and multiple amino- and carboxy-terminal fragments in
plasma and BALF. Increases in endostatin occur early after
OLV and LPS challenge in human volunteers but this is com-
partmentalised to the lung.
Endostatin was detectable in the plasma of all normal subjects
studied suggesting a physiological role in the homeostasis of
angiogenesis. Elevated endostatin levels have previously been
reported in the plasma of patients with preeclampsia, a condi-
tion associated with pan-endothelial damage [16]. Similarly, in
this study, median plasma level of endostatin in ALI patients
were elevated in comparison to both those at risk and normal
controls. Plasma levels of endostatin correlated with the sever-
ity of the systemic physiological insult rather than lung injury
per se. The observed relationship between BALF endostatin
and protein permeability index, and the apparent plasma
endostatin: ELF endostatin gradient in most of our patients fur-
ther suggest that alveolar levels of endostatin are raised at
least in part because of leakage from the microvasculature into
the alveolus at sites of inflammation of the alveolar-capillary
membrane. However, in some patients, calculated ELF levels
were higher than plasma supporting a role for alveolar gener-
ation of endostatin from the type XVIII collagen precursors that
we have shown are present.
Endostatin was also elevated in the BALF but not plasma of
patients with sepsis who were at risk of ALI. In order to study
the time course of changes in endostatin, we evaluated
changes in response to two injurious stimuli: OLV and LPS
challenge. Both these stimuli induce BAL neutrophilia and
increased the PPI in the volunteers/patients. Endostatin was
elevated in the BALF but not plasma of the patients after an
average of 2.5 hours of OLV and after six hours in the LPS-
challenged patients. Thus, endostatin release appears to be
compartmentalised to the lung early after such localised injuri-
ous stimuli. The relationships of BALF endostatin with PPI in
these in vivo models of the early response to ALI and in estab-
lished ALI suggest that endostatin generation might be useful
as a measure of alveolar capillary damage and support a
potential pathophysiological role.
Endostatin is derived from collagen XVIII which is a major pro-
teoglycan of both endothelial and epithelial basement mem-
brane zones. Specialised capillaries, such as lung alveoli,
express type XVIII collagen in their basement membranes.
Three forms of collagen XVIII precursor, designated the
SHORT, the MIDDLE and the LONG/frizzled variants, are dif-
ferentially expressed in normal human tissues. The SHORT
form predominates in vascular basement membranes [7],
whereas the MIDDLE and the LONG forms are abundantly
expressed in hepatocytes and are circulating plasma proteins
[31,32]. Furthermore, proteolytic degradation of type XVIII col-
lagen can generate multiple carboxy-terminal fragments of pre-
cursor collagen XVIII [33,34]. Clearly, therefore, elevated
endostatin levels could arise because of cleavage of elevated
circulating LONG forms and/or cleavage of the SHORT form
at sites of inflammation within the alveolar-capillary membrane.
Our immunoprecipitation and western blot results suggest
that degradation products of the LONG type XVIII collagen are
elevated in both the plasma and BALF of patients with ALI.
Proteolytic cleavage of the carboxy end of collagen XVIII has
been demonstrated for many enzymes including elastases,
cathepsins and matrix metalloproteinases (MMP), which have
been implicated in the pathogenesis of ALI [28,34,35]. West-
ern blotting of ALI BALF with antibody against the carboxy-ter-
minal of collagen XVIII demonstrated multiple endostatin-like
Figure 7
Western blot by anti-endostatin antibody HES.6 Western blot by anti-endostatin antibody HES.6. It shows endostatin-
like degradation products in bronchoalveolar lavage fluid (BALF) of 
patients with acute lung injury. Positive control was a recombinant 
human endostatin carrying a histidine tag (molecular weight of 22 kda). 
ALI = acute lung injury.Critical Care    Vol 13 No 2    Perkins et al.
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fragments similar in size to those produced by MMP degrada-
tion. These fragments may be important because they are
known to be bioactive and inhibit β-fibroblast growth factor-
induced endothelial cell proliferation and migration [28].
What are the implications of our findings for alveolar capillary
repair in ALI? Previous studies using the animal corneal micro-
pocket assay have demonstrated that BALF has a strong ang-
iogenic potential that is related to elevated CXC chemokine
levels [36]. In contrast, when looking at human primary lung
microvascular endothelial cells, ALI BALF caused cell death in
a TNF- and oncostatin-dependent manner [37]. Given the
known anti-endothelial actions of endostatin, the elevated lev-
els of endostatin seen in our patients may play a role in such
endothelial toxicity.
In addition to effects on endothelial cells, we have recently
reported that endostatin inhibits the proliferation and in vitro
wound repair responses of both distal small airway epithelial
cells, and primary human type II epithelial cells [38]. Thus ele-
vated levels of endostatin within the lung may also play a role
in aberrant epithelial repair mechanisms in ALI. The observed
relationships in this study between endostatin levels, the
degree of neutrophilic inflammation and physiological severity
suggest the multiple cellular effects of endostatin within the
lung might be of clinical importance.
This study has several limitations. Firstly, despite several
attempts, we were unable to detect plasma endostatin frag-
ments by immunoprecipitation and western blotting with the
HES.6 antibody, which appears unsuitable for plasma
endostatin estimation.
Secondly, there were a number of drop outs in our sequential
assessments, for clinical reasons (extubation, death or con-
traindication to bronchoscopy). We do not believe the results
have been biased by this because there were no baseline dif-
ferences in endostatin between those re-studied at day 4 and
those not. Thirdly, it would be interesting to observe the effect
of neutralising endostatin bioactivity in BALF on endothelial
cell viability. Unfortunately, no effective specific inhibitor for the
bioactivity of endostatin is currently available as endostatin has
a wide variety of effects on endothelial cells influencing nearly
12% of the genome via a variety of mechanisms [39]. Clearly
in order to firmly establish the pathophysiological importance
of endostatin release in the development of lung injury further
study in animal knock-out models would be required.
Conclusions
To our knowledge, this is the first report of the presence of
endostatin in plasma and BALF of humans with ALI. It is clear
that ALI patients have persistently elevated alveolar endostatin
levels during the early course of the disease. Our models of
the early onset of lung injury suggest these changes occur
very early in the injurious process. As endostatin may adversely
affect both alveolar-barrier endothelial and epithelial cells, its
presence within both the circulation and the lung may have a
pathophysiological role in ALI that warrants further evaluation.
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